Contact dermatitis · 2021
Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mercader-García Pedro, Pastor-Nieto María Antonia, Gonzalez-Perez Ricardo, Cordoba-Guijarro Susana, Gimenez-Arnau Ana María, Ruiz-Gonzalez Inmaculada, Mora-Fernández Verónica, Miquel Javier, Silvestre-Salvador Juan Francisco, Ortiz-Frutos Francisco Javier, Sanz-Sanchez Tatiana, Rodriguez-Serna Mercedes, Perez-Feal Patricia, Sánchez-Pérez Javier, Heras-Mendaza Felipe, Serra-Baldrich Ester, Zaragoza-Ninet Violeta, Hervella-Garces Marcos, Gatica-Ortega María Elena, García-Doval Ignacio, Descalzo Miguel Ángel, Borrego Leopoldo, REIDAC group
Аннотация
BACKGROUND: Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of this century. In 2008, this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN has progressively decreased. Despite that gradual decline, MDBGN is still patch-tested in most baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients, and the relevance of positive patch tests in a nationwide Spanish registry (REIDAC).
PATIENTS AND METHODS: We evaluated consecutively patch-tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests.
RESULTS: One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case.
CONCLUSION: Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable.
PATIENTS AND METHODS: We evaluated consecutively patch-tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests.
RESULTS: One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case.
CONCLUSION: Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable.